Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum‐pemetrexed for T790M mutation‐positive advanced non–small cell lung cancer-Reference-Cited by-同舟云学术

Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum‐pemetrexed for T790M mutation‐positive advanced non–small cell lung cancer

Published:2019-11-26 Issue:2 Volume:126 Page:373-380
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Papadimitrakopoulou Vassiliki A.¹,Han Ji‐Youn²,Ahn Myung‐Ju³,Ramalingam Suresh S.⁴^ORCID,Delmonte Angelo⁵,Hsia Te‐Chun⁶,Laskin Janessa⁷,Kim Sang‐We⁸,He Yong⁹^ORCID,Tsai Chun‐Ming¹⁰,Hida Toyoaki¹¹,Maemondo Makoto¹²,Kato Terufumi¹³,Jenkins Suzanne¹⁴,Patel Sabina¹⁴,Huang Xiangning¹⁴,Laus Gianluca¹⁵,Markovets Aleksandra¹⁶,Thress Kenneth S.¹⁷,Wu Yi‐Long¹⁸,Mok Tony¹⁹

Affiliation:

1. The University of Texas MD Anderson Cancer Center Houston Texas

2. Center for Lung Cancer National Cancer Center Goyang Republic of Korea

3. Samsung Medical Center School of Medicine Sungkyunkwan University Seoul Republic of Korea

4. Winship Cancer Institute Emory University Atlanta Georgia

5. Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS Meldola Italy

6. China Medical University Taichung City Taiwan

7. British Columbia Cancer Agency Vancouver British Columbia Canada

8. Asan Medical Center University of Ulsan College of Medicine Seoul Republic of Korea

9. Daping Hospital Third Military Medical University Chongqing China

10. Taipei Veterans General Hospital Taipei Taiwan

11. Aichi Cancer Center Nagoya Japan

12. Iwate Medical University School of Medicine Iwate Japan

13. Kanagawa Cancer Center Yokohama Japan

14. Precision Medicine, R&D Oncology AstraZeneca Cambridge United Kingdom

15. Global Medicines Development AstraZeneca Cambridge United Kingdom

16. Translational Medicine, Oncology AstraZeneca Boston Massachusetts

17. Oncology Translational Sciences, Innovative Medicines and Early Development Biotech Unit AstraZeneca Waltham Massachusetts

18. Guangdong General HospitalGuangdong Academy of Medical Sciences Guangzhou China

19. State Key Laboratory of South China Department of Clinical Oncology Chinese University of Hong Kong Hong Kong China

Funder

AstraZeneca

National Institutes of Health

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.32503

Reference15 articles.

1. AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer

2. Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer

3. Osimertinib in UntreatedEGFR-Mutated Advanced Non–Small-Cell Lung Cancer

4. European Medicines Agency.Tagrisso (Osimertinib): Summary of Product Characteristics. Accessed February 22 2019.https://www.ema.europa.eu/documents/product-information/tagrisso-epar-product-information_en.pdf

5. US Food and Drug Administration.Tagrisso (Osimertinib): Highlights of Prescribing Information. Accessed April 26 2018.https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208065s008lbl.pdf

Cited by 102 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical utility of repeated rebiopsy for EGFR T790M mutation detection in non-small cell lung cancer;Frontiers in Oncology;2024-08-26

2. Identification and Application of Emerging Biomarkers in Treatment of Non-Small-Cell Lung Cancer: Systematic Review;Cancers;2024-06-26

3. Benefits of NGS in Advanced Lung Adenocarcinoma Vary by Populations and Timing of Examination;International Journal of Molecular Sciences;2024-06-25

4. Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey.;Lung Cancer: Targets and Therapy;2024-06

5. Non-small cell lung cancer: an update on emerging EGFR-targeted therapies;Expert Opinion on Emerging Drugs;2024-04-02